A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

NCT05687890 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Kidney Disease
IgA Nephropathy

Interventions

DRUG: Placebo of SC0062
DRUG: SC0062 low dose
DRUG: SC0062 medium dose
DRUG: SC0062 high dose

Sponsor

Biocity Biopharmaceutics Co., Ltd.